期刊
CANCER LETTERS
卷 280, 期 1, 页码 1-14出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.10.045
关键词
Met; Receptor tyrosine kinase; Targeted therapy; Hepatocyte growth factor
类别
资金
- NCI, Department of Health and Human Services [CA85915]
- Center for Targeted Therapy of the University of Texas M.D. Anderson Cancer Center
Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据